Kidney Cancer News and Research RSS Feed - Kidney Cancer News and Research

Kidney cancer is usually defined is a cancer that originates in the kidney. The two most common types of kidney cancer, reflecting their location within the kidney, are renal cell carcinoma (RCC) and urothelial cell carcinoma (UCC) of the renal pelvis.
UNM Cancer Center enrolls first patient in phase 3 international clinical trial for kidney cancer vaccine

UNM Cancer Center enrolls first patient in phase 3 international clinical trial for kidney cancer vaccine

The University of New Mexico Cancer Center recently enrolled its first patient in a phase 3 international clinical trial to test a personalized vaccine against metastatic kidney cancer. Kidney cancer has proven particularly difficult to treat with chemotherapy, and numerous attempts to create a kidney cancer vaccine have not improved survival rates. [More]
Two case studies provide potential new avenue for treatment of kidney cancer

Two case studies provide potential new avenue for treatment of kidney cancer

UT Southwestern Medical Center Kidney Cancer Program investigators have published what is believed to be the first reported successful use of stereotactic body radiation therapy for an often deadly complication of kidney cancer. [More]
Researchers develop noninvasive method to detect kidney cancer early

Researchers develop noninvasive method to detect kidney cancer early

If kidney cancer is diagnosed early — before it spreads — 80 percent of patients survive. However, finding it early has been among the disease's greatest challenges. [More]
Study: Cancer drug may help reduce bleeding in HHT patients

Study: Cancer drug may help reduce bleeding in HHT patients

A cancer drug that helps keep tumors from growing blood vessels may help patients with a rare genetic condition in which malformed vessels increase their risk for bleeding and anemia. [More]
Today’s “World Kidney Day” promotes kidney health for all

Today’s “World Kidney Day” promotes kidney health for all

Recent surveys have shown that the general public’s understanding about what our kidneys do and what the risk factors for kidney disease are, is astoundingly poor. In the UK, five leading kidney charities are joining forces in the campaign “Kidney Charities Together,” which calls for urgent action to be taken to raise awareness of kidney disease. [More]
1 in 5 of the UK population could be walking around with ‘ticking time bomb’

1 in 5 of the UK population could be walking around with ‘ticking time bomb’

Kidney Research UK polled 2,000 adults across the UK to find out just how much people know about the disease. Startlingly, almost three quarters (74%) of those polled claim to have limited or no knowledge of kidney disease, its causes or its symptoms. [More]
New study assesses suicide risks in older, white males with advanced bladder cancer

New study assesses suicide risks in older, white males with advanced bladder cancer

Older, single white males with advanced bladder cancer have the highest suicide risk among those with other cancers of the male genitals and urinary system, researchers report. [More]
Higher intake of lycopene may lower risk of renal cell carcinoma in postmenopausal women

Higher intake of lycopene may lower risk of renal cell carcinoma in postmenopausal women

A higher intake by postmenopausal women of the natural antioxidant lycopene, found in foods like tomatoes, watermelon and papaya, may lower the risk of renal cell carcinoma, a type of kidney cancer. [More]
Bionomics to present data from DisrupTOR-1 trial at ASCO Genitourinary Cancers Symposium

Bionomics to present data from DisrupTOR-1 trial at ASCO Genitourinary Cancers Symposium

Bionomics Limited is to present important additional data from the DisrupTOR-1 trial of BNC105 in patients with metastatic renal cancer at the ASCO Genitourinary Cancers Symposium in Orlando, Florida. The data will be presented by Dr. Sumanta Pal of the City of Hope Comprehensive Cancer Center in California in his poster presentation. [More]
Sorafenib, sunitinib provide no benefit to patients with locally advanced kidney cancer

Sorafenib, sunitinib provide no benefit to patients with locally advanced kidney cancer

Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib. The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery (5.6 years) and those treated with placebo (5.7 years). [More]
Two widely used targeted therapy drugs not effective in preventing return of kidney cancer

Two widely used targeted therapy drugs not effective in preventing return of kidney cancer

Two widely used targeted therapy drugs— approved by the FDA for use in metastatic kidney cancer —are no more effective than a placebo in preventing return of the disease to increase life spans of patients suffering from advanced kidney cancer after surgery, according to new results to be presented by a researcher at the University of Pennsylvania's Abramson Cancer Center during the 2015 Genitourinary Cancers Symposium. [More]
Study results report no benefit from use of sunitinib, sorafenib among patients with kidney cancer

Study results report no benefit from use of sunitinib, sorafenib among patients with kidney cancer

Research results highlighted today at the press conference of a major medical meeting report no benefit from the use of either Sutent (sunitinib) or Nexavar (sorafenib) among patients with locally advanced renal cell carcinoma at high risk of recurrence, the ECOG-ACRIN Cancer Research Group announced. [More]
Henry Ford physicians suction cancerous tumor from vein in metastatic kidney cancer patient

Henry Ford physicians suction cancerous tumor from vein in metastatic kidney cancer patient

Physicians at Henry Ford Hospital successfully suctioned a cancerous tumor from a major vein in a patient with metastatic kidney cancer, clearing the way for him to undergo a minimally-invasive kidney removal. This allowed him to participate in a clinical trial using genetic material from his tumor to produce a vaccine to help fight his metastatic disease. [More]
NanoGap sensor helps detect bladder and kidney cancer at an early stage

NanoGap sensor helps detect bladder and kidney cancer at an early stage

A new mobile device that allows bladder and kidney cancer to be detected at an early stage. This is being worked on by Wilfred van der Wiel, professor of nanoelectronics at the University of Twente MESA+ research institute. Thanks to this method, it is possible to read from DNA cells whether their carrier has bladder or kidney cancer. [More]
Henry Ford physicians use AngioVac device to remove tumor in kidney cancer patient

Henry Ford physicians use AngioVac device to remove tumor in kidney cancer patient

Physicians at Henry Ford Hospital successfully suctioned a cancerous tumor from a major vein in a patient with metastatic kidney cancer, clearing the way for him to undergo a minimally-invasive kidney removal. [More]
Lund researchers find new way to identify malignant tumours in children

Lund researchers find new way to identify malignant tumours in children

A research group at Lund University in Sweden has found a new way to identify the most malignant tumours in children. The method involves studying genetic 'micro-variation', rather than the presence of individual mutations. [More]
Close, active monitoring of small renal tumors linked to low rates of death

Close, active monitoring of small renal tumors linked to low rates of death

In patients likely to have surgery, close, active monitoring of small renal tumors confined to the kidneys is associated with low rates of tumor growth or death, according to a study by a researcher at the Icahn School of Medicine at Mount Sinai published in the September issue of The Journal of Urology. [More]
Study: Patients with operable kidney cancers more likely to have partial nephrectomy

Study: Patients with operable kidney cancers more likely to have partial nephrectomy

Patients with operable kidney cancers were more likely to have a partial nephrectomy -- the recommended treatment for localized tumors -- when treated in hospitals that were early adopters of robotic surgery, according to a new study. [More]
Study suggests that hospitals perform more partial nephrectomies after acquiring robots

Study suggests that hospitals perform more partial nephrectomies after acquiring robots

Hospitals with robotic surgical systems are more likely to perform "nephron-sparing" partial nephrectomy--a recommended alternative to removal of the entire kidney--in patients with kidney cancer, reports a study in the December issue of Medical Care. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health. [More]
Amgen's XGEVA (denosumab) receives FDA approval for treatment of hypercalcemia of malignancy

Amgen's XGEVA (denosumab) receives FDA approval for treatment of hypercalcemia of malignancy

Amgen today announced that the U.S. Food and Drug Administration has approved a new indication for XGEVA (denosumab) for the treatment of hypercalcemia of malignancy (HCM) refractory to bisphosphonate therapy. [More]
Advertisement